

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

Date: 29th October, 2021

To,
Bombay Stock Exchange Limited
Department of Corporate Services
25th Floor, P. J. Towers, Dalal Street,
Mumbai-400001

Script Id : 506365

Subject : SUBMISSION OF COMPLIANCES UNDER SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sirs,

We are enclosing herewith Quarterly Compliances pursuant to Securities And Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Quarter and Half Year ended 30th September, 2021 as under -


1.	Regulation 33	Un-audited Quarterly and Half Yearly Financial Results along with Statement of Assets And Liabilities for the Quarter and Half Year ended 30/09/2021 along with Limited Review Report issued by our Auditors, M/s. Sanjay Rane & Associates, Chartered Accountant, Mumbai
2.		Outcome of the Board Meeting Held on 29/10/2021

You are requested to take this on your records.

Thanking You.

Yours Faithfully,

FOR CHEMO PHARMA LABORATORIES LIMITED



ASHOK SOMANI
DIRECTOR
(DIN- 03063364)



Place: Mumbai
Encl: as above

Sanjay Rane & Associates

CHARTERED ACCOUNTANTS

C-403, Marathon Next Gen. Innova,
Opp. Peninsula Corporate Park,
Off Ganpatrao Kadam Marg,
Lower Parel, Mumbai-400 013.

Phone : 49198585
Telefax : 49198521
Email : admin@ssrane.net
Website : www.ssraneandco.com

LIMITED REVIEW REPORT

We have reviewed the accompanying Statement of unaudited financial results of **CHEMO PHARMA LABORATORIES LIMITED** for the quarter ended **September 30, 2021**. This Statement is the responsibility of the Company's management and has been approved by the Board of Directors / committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, Engagement to Review Financial Statements issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our notice that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable Accounting Standards and other recognized accounting practices and polices has not disclosed the information required to be disclosed in terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Sanjay Rane and Associates

Chartered Accountants

Firm Reg. No. 121089W



CA. Abhijeet Deshmukh

Partner

Membership No. 129145



Date: October 26, 2021

Place: Mumbai

UDIN: 21129145AAABED1802

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001
 • Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K
 Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER 2021

Sr. No.	Particulars	(Rupees in Thousand)					
		Quarter Ended			Half Year Ended		Year Ended
		30th Sept 2021	30th June 2021	30th Sept 2020	30th Sept 2021	30th Sept 2020	31st March 2021
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	
I	Revenue from Operations	-	-	-	-	-	-
II	Other Income	1,896	1,092	1,428	2,986	2,991	6,680
III	Total Revenue (I + II)	1,896	1,092	1,428	2,986	2,991	6,680
IV	Expenses						
	(1) Cost Materials consumed	-	-	-	-	-	-
	(2) Purchase of Stock-in-Trade	-	-	-	-	-	-
	(3) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	-	-	-	-	-	-
	(4) Employee Benefits Expenses	365	352	216	718	461	1,262
	(5) Depreciation and Amortisation Expenses	91	-	-	91	-	239
	(6) Administrative and Other Expenses	321	429	200	747	631	2,071
	(7) Finance Costs	-	-	-	-	-	-
	Total Expenses	777	781	416	1,556	1,092	3,572
V	Profit/(Loss) before Exceptional and Extra ordinary Items and tax (III - IV)	1,119	311	1,012	1,430	1,899	3,108
VI	Exceptional Items	-	-	-	-	-	-
VII	Net Profit/(Loss) before Extra ordinary Items and Tax (V - VI)	1,119	311	1,012	1,430	1,899	3,108
VIII	Extra Ordinary Items	-	-	-	-	-	-
IX	Profit/(Loss) before Tax (VII-VIII)	1,119	311	1,012	1,430	1,899	3,108
X	Tax Expenses						
	(1) Current Tax	-	-	-	-	-	503
	(2) Tax Adjustment Previous Year	-	-	-	-	56	104
	(3) Deferred Tax	-	-	-	-	-	-
XI	Profit/(Loss) for the period from continuing operations (IX - X)	1,119	311	1,012	1,430	1,843	2,501
XII	Profit/(Loss) from discontinuing operations	-	-	-	-	-	-
XIII	Tax Expenses of discontinuing operations	-	-	-	-	-	-
XIV	Profit/(Loss) from discontinuing operations (after tax) (XII - XIII)	-	-	-	-	-	-
XV	Profit/(Loss) for the period (XI - XIV)	1,119	311	1,012	1,430	1,843	2,501
XVI	Other Comprehensive Income						
	A (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	B (i) Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
XVII	Total Comprehensive Income for the period (XV+XVI) (Comprising Profit (Loss) and Other Comprehensive Income for the period)	1,119	311	1,012	1,430	1,843	2,501
XVIII	Earnings per Share :						
	(1) Basic	0.75	0.21	0.67	0.95	1.23	1.67
	(2) Diluted						

Notes :

- This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of the Companies (Indian Accounting Standard) Rules, 2015 and Companies (Indian Accounting Standard) Accounting Rules, 2016.
- The above Unaudited Financial Results for the Quarter & Half Year Ended 30.09.2021 have been reviewed by the Audit Committee in their Meeting held on .10.2021 and approved by the Board of Directors of its Meeting held on . 10.2021. The Report of Auditors M/s Sanjay Rane & Associates was also taken on record by the Board in its Meeting.
- The Company is having only one Segment and no other reportable segment in terms of Ind AS 108 in 'Operating Segment'.

For Chemo Pharma Laboratories Limited

Ashok Somani

Ashok Somani

Director

DIN : 03063364

Date : 29th October, 2021

Place : Mumbai



CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office :- Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE STATEMENT OF ASSETS & LIABILITIES FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER, 2021

(Rupees in Thousand)

Sr. No.	PARTICULARS	As at 30.09.2021 Unaudited	As at 31.03.2021 Audited
1	ASSETS		
1	Non-Current Assets		
	(A) Property, Plant & Equipment	490	522
	(B) Financial Assets		
	(i) Investment	9,653	407
	(ii) Long Term Loans	20,000	-
	Total Non-Current Assets	30,143	929
2	Current Assets		
	(A) Financial Assets		
	(i) Cash & Cash Equivalents	78,502	1,08,711
	(ii) Other Current Assets	2,063	294
	(ii) Loans	541	-
	(B) Other Current Assets	143	95
	Total Current Assets	81,249	1,09,100
	TOTAL ASSETS	1,11,392	1,10,029
2	EQUITY AND LIABILITIES		
1	Equity		
	(a) Equity Share Capital	15,000	15,000
	(b) Other Equity (Reserve & Surplus)	96,378	94,948
	Total Equity	1,11,378	1,09,948
2	Liabilities		
1	Non-Current Liabilities	-	-
2	Current Liabilities		
	(A) Financial Liabilities		
	(i) Other Current Liabilities	14	81
	(ii) Provisions	-	-
	Total Current Liabilities	14	81
	TOTAL EQUITY AND LIABILITIES	1,11,392	1,10,029

By Order of the Board

For Chemo - Pharma Laboratories Limited

Ashok Somani

Ashok Somani

Director

DIN : 03063364



Date : 29th October, 2021

Place : Mumbai

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

STANDALONE CASH FLOW STATEMENT FOR HALF YEAR ENDED AS ON 30TH SEPTEMBER 2021

(Rupees in Thousand)

PARTICULARS	Half Year Ended 30.09.2021 Unaudited	Year Ended 31.03.2021 Audited
A. CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit before tax and extraordinary items	1,430	3,107
Adjustment for		
Depreciation	91	239
Dividend received	(50)	(4)
Interest received	(2,513)	(5,309)
Liabilities written back	-	-
Operating profit before working capital changes	(1,042)	(1,967)
Adjustment for		
Increase (Decrease) in other Current Liabilities	(67)	(1,368)
Decrease (increase) in Current Assets	(2,358)	128
Increase in Loans Given	(20,000)	19,568
Increase in Fixed Assets	(59)	(14)
Cash Generated From Operation	(22,484)	18,314
Taxes Paid	-	(863)
A. Cash Flow From Operating Activities	(23,526)	15,484
B. CASH FLOW FROM INVESTING ACTIVITIES		
Dividend received	50	4
Interest received	2,513	5,309
Increased / (Decrease) in Investment	(9,246)	(170)
Cash Flow From Investing Activities	(6,683)	5,143
C. CASH FLOW FROM FINANCING ACTIVITIES		
Interest Paid	-	-
Cash Flow From Financing Activities	-	-
Net increase/(decrease) in cash and cash Equivalents	(30,209)	20,627
Opening balance of Cash and Cash Equivalents	1,08,711	88,084
Closing Balance Of Cash and Cash Equivalents	78,502	1,08,711

For Chemo Pharma Laboratories Limited



Ashok Somani

Ashok Somani

Director

DIN : 03063364

Date : 29th October, 2021

Place : Mumbai

CHEMO PHARMA LABORATORIES LIMITED

Registered Office: 5-Kumud Apartment Co. Op. HSG. SOC. Ltd., Karnik Road, Chikan Ghar, Kalyan, Dist. Thane - 421301

• Corporate Office : - Empire House, 3rd Floor, 214, Dr. D. N. Road, Fort, Mumbai - 400 001

• Tel.No. (022) 22078381, 22078382 • CIN No.: L99999MH1942PLC003556 • PAN No.: AAACC2056K

Website: www.thechemopharmalaboratoriesltd.com • Email ID: chemopharmalab@gmail.com

RECONCILIATION OF STANDALONE NET PROFIT FOR THE QUARTER & HALF YEAR ENDED 30TH SEPTEMBER, 2021

(Rs. in Thousand)

PARTICULARS	STANDALONE					
	UNAUDITED QUARTER ENDED			UNAUDITED HALF YEAR ENDED		AUDITED YEAR ENDED
	30.09.2021	30.06.2021	30.09.2020	30.09.2021	30.09.2020	31.03.2021
Reconciliation of Profit After Tax as reported earlier:						
Net Profit / (Loss) for the Period (as per AS)	1,119.00	311.00	1,012.00	1,430.00	1,843.00	2,501.00
Benefit / (Charge):	-	-	-	-	-	-
Impact of Deferred Income (Government Grant) Amortized to Income	-	-	-	-	-	-
Impact of Fair Valuation of Financial Instruments	-	-	-	-	-	-
Impact of Actuarial Gain / Loss Taken OCI	-	-	-	-	-	-
Impact of Adjustment of Deferred Tax	-	-	-	-	-	-
Net Profit / (Loss) for the Period (as per AS)	1,119.00	311.00	1,012.00	1,430.00	1,843.00	2,501.00

Date: 29th October, 2021
Place: Mumbai



For Chemo Pharma Laboratories Limited

Ashok Somani
Director
DIN : 03063364